Cargando…

A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies

Human-relevant systems that mimic the 3D tumor microenvironment (TME), particularly the complex mechanisms of immuno-modulation in the tumor stroma, in a reproducible and scalable format are of high interest for the drug discovery industry. Here, we describe a novel 3D in vitro tumor panel comprisin...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Bin, Schüler, Julia, Harrod, Christopher M., Lashuk, Kanstantsin, Bomya, Zoji, Hribar, Kolin C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137152/
https://www.ncbi.nlm.nih.gov/pubmed/37190054
http://dx.doi.org/10.3390/cells12081145
_version_ 1785032390965460992
author Xue, Bin
Schüler, Julia
Harrod, Christopher M.
Lashuk, Kanstantsin
Bomya, Zoji
Hribar, Kolin C.
author_facet Xue, Bin
Schüler, Julia
Harrod, Christopher M.
Lashuk, Kanstantsin
Bomya, Zoji
Hribar, Kolin C.
author_sort Xue, Bin
collection PubMed
description Human-relevant systems that mimic the 3D tumor microenvironment (TME), particularly the complex mechanisms of immuno-modulation in the tumor stroma, in a reproducible and scalable format are of high interest for the drug discovery industry. Here, we describe a novel 3D in vitro tumor panel comprising 30 distinct PDX models covering a range of histotypes and molecular subtypes and cocultured with fibroblasts and PBMCs in planar (flat) extracellular matrix hydrogels to reflect the three compartments of the TME—tumor, stroma, and immune cells. The panel was constructed in a 96-well plate format and assayed tumor size, tumor killing, and T-cell infiltration using high-content image analysis after 4 days of treatment. We screened the panel first against the chemotherapy drug Cisplatin to demonstrate feasibility and robustness, and subsequently assayed immuno-oncology agents Solitomab (CD3/EpCAM bispecific T-cell engager) and the immune checkpoint inhibitors (ICIs) Atezolizumab (anti-PDL1), Nivolumab (anti-PD1) and Ipilimumab (anti-CTLA4). Solitomab displayed a strong response across many PDX models in terms of tumor reduction and killing, allowing for its subsequent use as a positive control for ICIs. Interestingly, Atezolizumab and Nivolumab demonstrated a mild response compared to Ipilimumab in a subset of models from the panel. We later determined that PBMC spatial proximity in the assay setup was important for the PD1 inhibitor, hypothesizing that both duration and concentration of antigen exposure may be critical. The described 30-model panel represents a significant advancement toward screening in vitro models of the tumor microenvironment that include tumor, fibroblast, and immune cell populations in an extracellular matrix hydrogel, with robust and standardized high content image analysis in a planar hydrogel. The platform is aimed at rapidly screening various combinations and novel agents and forming a critical conduit to the clinic, thus accelerating drug discovery for the next generation of therapeutics.
format Online
Article
Text
id pubmed-10137152
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101371522023-04-28 A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies Xue, Bin Schüler, Julia Harrod, Christopher M. Lashuk, Kanstantsin Bomya, Zoji Hribar, Kolin C. Cells Article Human-relevant systems that mimic the 3D tumor microenvironment (TME), particularly the complex mechanisms of immuno-modulation in the tumor stroma, in a reproducible and scalable format are of high interest for the drug discovery industry. Here, we describe a novel 3D in vitro tumor panel comprising 30 distinct PDX models covering a range of histotypes and molecular subtypes and cocultured with fibroblasts and PBMCs in planar (flat) extracellular matrix hydrogels to reflect the three compartments of the TME—tumor, stroma, and immune cells. The panel was constructed in a 96-well plate format and assayed tumor size, tumor killing, and T-cell infiltration using high-content image analysis after 4 days of treatment. We screened the panel first against the chemotherapy drug Cisplatin to demonstrate feasibility and robustness, and subsequently assayed immuno-oncology agents Solitomab (CD3/EpCAM bispecific T-cell engager) and the immune checkpoint inhibitors (ICIs) Atezolizumab (anti-PDL1), Nivolumab (anti-PD1) and Ipilimumab (anti-CTLA4). Solitomab displayed a strong response across many PDX models in terms of tumor reduction and killing, allowing for its subsequent use as a positive control for ICIs. Interestingly, Atezolizumab and Nivolumab demonstrated a mild response compared to Ipilimumab in a subset of models from the panel. We later determined that PBMC spatial proximity in the assay setup was important for the PD1 inhibitor, hypothesizing that both duration and concentration of antigen exposure may be critical. The described 30-model panel represents a significant advancement toward screening in vitro models of the tumor microenvironment that include tumor, fibroblast, and immune cell populations in an extracellular matrix hydrogel, with robust and standardized high content image analysis in a planar hydrogel. The platform is aimed at rapidly screening various combinations and novel agents and forming a critical conduit to the clinic, thus accelerating drug discovery for the next generation of therapeutics. MDPI 2023-04-13 /pmc/articles/PMC10137152/ /pubmed/37190054 http://dx.doi.org/10.3390/cells12081145 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Xue, Bin
Schüler, Julia
Harrod, Christopher M.
Lashuk, Kanstantsin
Bomya, Zoji
Hribar, Kolin C.
A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies
title A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies
title_full A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies
title_fullStr A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies
title_full_unstemmed A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies
title_short A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies
title_sort novel hydrogel-based 3d in vitro tumor panel of 30 pdx models incorporates tumor, stromal and immune cell compartments of the tme for the screening of oncology and immuno-therapies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137152/
https://www.ncbi.nlm.nih.gov/pubmed/37190054
http://dx.doi.org/10.3390/cells12081145
work_keys_str_mv AT xuebin anovelhydrogelbased3dinvitrotumorpanelof30pdxmodelsincorporatestumorstromalandimmunecellcompartmentsofthetmeforthescreeningofoncologyandimmunotherapies
AT schulerjulia anovelhydrogelbased3dinvitrotumorpanelof30pdxmodelsincorporatestumorstromalandimmunecellcompartmentsofthetmeforthescreeningofoncologyandimmunotherapies
AT harrodchristopherm anovelhydrogelbased3dinvitrotumorpanelof30pdxmodelsincorporatestumorstromalandimmunecellcompartmentsofthetmeforthescreeningofoncologyandimmunotherapies
AT lashukkanstantsin anovelhydrogelbased3dinvitrotumorpanelof30pdxmodelsincorporatestumorstromalandimmunecellcompartmentsofthetmeforthescreeningofoncologyandimmunotherapies
AT bomyazoji anovelhydrogelbased3dinvitrotumorpanelof30pdxmodelsincorporatestumorstromalandimmunecellcompartmentsofthetmeforthescreeningofoncologyandimmunotherapies
AT hribarkolinc anovelhydrogelbased3dinvitrotumorpanelof30pdxmodelsincorporatestumorstromalandimmunecellcompartmentsofthetmeforthescreeningofoncologyandimmunotherapies
AT xuebin novelhydrogelbased3dinvitrotumorpanelof30pdxmodelsincorporatestumorstromalandimmunecellcompartmentsofthetmeforthescreeningofoncologyandimmunotherapies
AT schulerjulia novelhydrogelbased3dinvitrotumorpanelof30pdxmodelsincorporatestumorstromalandimmunecellcompartmentsofthetmeforthescreeningofoncologyandimmunotherapies
AT harrodchristopherm novelhydrogelbased3dinvitrotumorpanelof30pdxmodelsincorporatestumorstromalandimmunecellcompartmentsofthetmeforthescreeningofoncologyandimmunotherapies
AT lashukkanstantsin novelhydrogelbased3dinvitrotumorpanelof30pdxmodelsincorporatestumorstromalandimmunecellcompartmentsofthetmeforthescreeningofoncologyandimmunotherapies
AT bomyazoji novelhydrogelbased3dinvitrotumorpanelof30pdxmodelsincorporatestumorstromalandimmunecellcompartmentsofthetmeforthescreeningofoncologyandimmunotherapies
AT hribarkolinc novelhydrogelbased3dinvitrotumorpanelof30pdxmodelsincorporatestumorstromalandimmunecellcompartmentsofthetmeforthescreeningofoncologyandimmunotherapies